Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VRCA with free AI briefings, catalyst countdowns, and dilution alerts.

VRCA · Verrica Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.2M Cash on Hand
3.6mo Cash Runway
Follow VRCA by email Get an email when VRCA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VRCA, unsubscribe in one click. Privacy

📣 What VRCA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Part 1: VP-315 3 Day Dosing/Week Basal Cell Carcinoma Phase 2 · NCT05188729 Completed
Part 2: VP-315 2 Day Dosing/Week - Split Dose Basal Cell Carcinoma Phase 2 · NCT05188729 Completed
Part 2: VP-315 3 Day Dosing/Week - Loading Dose Basal Cell Carcinoma Phase 2 · NCT05188729 Completed
Part 2: VP-315 3 Day Dosing/Week - No Loading… Basal Cell Carcinoma Phase 2 · NCT05188729 Completed
Part 2: VP-315 3 Day Dosing/Week - Split Dose Basal Cell Carcinoma Phase 2 · NCT05188729 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VRCA holds $11.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 85 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRCA files for a raise →

👥 Who Owns VRCA

Insiders 67.6% Institutions (48 holders) 27% Public and other holders 5.4%
HolderTypeShares% of sharesAs of
Paul B Manning
Director, 10% owner · +687,690 options
Insider 4,316,285 25.13% 2025-11-25
BKB Growth Investments, LLC
10% owner
Insider 3,348,372 19.49% 2025-11-25
John A III Stalfort
Director · +561,797 options
Insider 1,873,800 10.91% 2024-11-22
Caligan Partners LP
See Remarks
Insider 923,910 5.38% 2025-12-26
Ted White
PRESIDENT AND CEO, Director
Insider 278,789 1.62% 2023-08-24
Jayson Rieger
CEO and President, Director · +1.53M options
Insider 207,838 1.21% 2026-08-14
Joe Bonaccorso
CHIEF COMMERCIAL OFFICER
Insider 187,738 1.09% 2023-08-24
Christopher G. Hayes
CHIEF LEGAL OFFICER · +250,000 options
Insider 176,458 1.03% 2025-03-14
Terry Kohler
CHIEF FINANCIAL OFFICER
Insider 125,000 0.73% 2023-08-24
Gary Goldenberg
Chief Medical Officer
Insider 120,110 0.70% 2023-08-24
David Zawitz
Chief Operating Officer · +1.12M options
Insider 27,000 0.16% 2026-08-17
John J. Kirby
Interim CFO · +884 options
Insider 23,962 0.14% 2026-08-18

Share count 17,178,786 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VRCA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRCA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.